News
XGN
1.420
+2.52%
0.035
Exagen to Announce First Quarter 2024 Results on May 13, 2024
Exagen Inc. Will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. Exagen is a leading provider of autoimmune testing. The Company will host a conference call to review the Company's results at 8:30am ET.
Barchart · 3d ago
Weekly Report: what happened at XGN last week (0422-0426)?
Weekly Report · 4d ago
Exagen Inc Board Reshuffle and New Class I Director Appointment
TipRanks · 04/26 12:42
*Exagen: Brian Birk, Ebetuel Pallares, Wendy Johnson to Step Down From Board, effective June 10 >XGN
Dow Jones · 04/26 12:32
*Exagen: Scott Kahn Joining Board >XGN
Dow Jones · 04/26 12:32
*Exagen Reducing Size of Board to Seven Directors From Nine >XGN
Dow Jones · 04/26 12:31
EXAGEN INC. ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS
Reuters · 04/26 12:30
Press Release: Exagen Inc. Announces Changes to the Board of Directors
Exagen Inc. Announces Changes to the Board of Directors. Scott Kahn, Ph.D. Is joining the Board as a Class I Director. The company is reducing the size of the Board from nine to seven. Exagen is a leading provider of autoimmune testing solutions.
Dow Jones · 04/26 12:30
Weekly Report: what happened at XGN last week (0415-0419)?
Weekly Report · 04/22 09:52
Weekly Report: what happened at XGN last week (0408-0412)?
Weekly Report · 04/15 09:48
Weekly Report: what happened at XGN last week (0401-0405)?
Weekly Report · 04/08 09:50
Weekly Report: what happened at XGN last week (0325-0329)?
Weekly Report · 04/01 09:50
Weekly Report: what happened at XGN last week (0318-0322)?
Weekly Report · 03/25 09:51
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
TipRanks · 03/20 09:56
Exagen’s Challenge: Strengthening Financial Controls to Restore Confidence and Secure Growth
TipRanks · 03/19 06:00
Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating
TipRanks · 03/18 23:05
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023
Exagen reported earnings per share of -31 cents. The company reported revenue of $13.77 million. Exagen's revenue was 19.07% better than the analyst estimate of $11.56 million for the quarter. The stock is down 1.7% today.
Investorplace · 03/18 16:52
Exagen reports Q4 results
Exagen reports Q4 results. Q4 total revenue was $13.8 million. Full year net loss was $23.7 million, on revenue of $52.5 million. Exagen is a biotechnology company with a focus on cancer treatment. The company's stock is down 7% in the last week.
Seeking Alpha · 03/18 15:27
Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers
Healthcare On the Move: Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers. S&P 500 Health Care Sector +0.1% to 1692.1. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/18 14:00
Exagen Inc reports results for the quarter ended in December - Earnings Summary
Exagen Inc reports results for the quarter ended in December. Revenue rose 7.2% to $13.77 million from a year ago. The company reported a quarterly loss of $5.57 million. Exagen Inc shares had fallen by 18.6% this quarter.
Reuters · 03/18 13:31
More
Webull provides a variety of real-time XGN stock news. You can receive the latest news about Exagen Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XGN
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.